Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 529

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 529
---
|
| 2024                                         |     | $ |   130 |   |
| 2025                                         |     |   |   320 |   |
| 2026                                         |     |   |   231 |   |
| 2027                                         |     |   |   280 |   |
| 2028                                         |     |   |   109 |   |
| Total minimum lease payments                 |     | $ | 1,070 |   |
| Less: amount representing interest           |     |   |  (124 | ) |
| Present value of operating lease liabilities |     | $ |   946 |   |
| Less: operating lease liabilities, current   |     |   |  (322 | ) |
| Operating lease liabilities, non-current     |     | $ |   624 |   |
| Remaining lease term (in years)              |     |   |  3.33 |   |
| Incremental borrowing rate                   |     |   |  7.62 | % |

F-48

The Company includes the option to renew the lease as part of the right of use lease asset and liability
when it is reasonably certain the Company will exercise the option. In general, the Company is not reasonably certain to exercise such options.

7. License Agreements

Bristol Myers Squibb Company License Agreement

On April 9, 2014, the Company entered into a license agreement (as amended, the “BMS License Agreement”) with BMS for exclusive rights for
certain patents and a non-exclusive license for certain technology and know-how pertaining to FYARRO.

The BMS License Agreement will remain in effect from the effective date of April 9, 2014 until expiration of all milestone and royalty payment
obligations under the agreement, unless terminated by either of the parties upon giving advance notice as specified in the BMS License Agreement. Under the terms of the BMS License Agreement, BMS agreed to supply the Company with licensed products
of FYARRO necessary for clinical or non-clinical development.

Under the terms of the BMS License Agreement, BMS
is entitled to receive certain development milestone payments, royalties on net sales from licensed products under the agreement and any sublicense fees. During the three months ended September 30, 2024 and 2023, royalties on net product sales
were $0.5 million and $0.4 million, respectively. During the nine months ended September 30